The Price is Right? – Delivering UK access for niche patient populations

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), takes place on Thursday 12th November, 14:00 GMT / 15:00 CET and will introduce the new NIHR National Patient Recruitment Centres and look at how the NPRCs will take a patient-centric approach to pharmaceutical research.

With exclusive surveys of the continuing medical education (CME) needs of haematologists/oncologists (haem/oncs), this webinar will look at where physicians are going for their learning needs and what effect the COVID-19 pandemic continues to have.

The Behavioural insights into haem/onc clinical decision-making webinar, in association with Medscape, will take place on Thursday 3rd September from 13:00-14:00 (BST)/14:00-15:00 (CEST).

This webinar will look at how pharma can use modular content in its multichannel and omnichannel strategies.

Presented in association with Viseven, it will also include ways to improve, and speed up, the content supply chain and hear how Novo Nordisk designs and executes customer engagement journeys

COVID-19 has brought many changes to the pharmaceutical industry, among them a need to change how pharma companies engage with HCPs and transform their approach to digital channels.

This webinar, held in association with Veeva, will present some exclusive market observations from before and during the COVID crisis and explain how pharmaceutical companies can increase their digital IQ and accelerate the move to digital.

As use of real-world evidence increases there is an opportunity to improve the patient experience.

In addition to key steps forward with the establishment of Health Data Research UK and NHSX, information governance will be key, as is alignment to UK and EU regulations such as the July 2019 DHSC Framework for the Value of NHS Research and GDPR.

Insights on the impact of COVID-19 for pharma and biotech companies and considerations for a post-coronavirus new normal in life sciences and healthcare.

It will also discuss the UK response to the emergency, clinical trials and how digital health has met the COVID-19 challenge for healthcare professionals, patients and industry.

COVID-19 is making digital transformation even more pressing for pharmaceutical companies.

Amid the coronavirus pandemic digital health offers many ways to develop public utility projects and enhance healthcare communications.

Overview

This April webinar is part of IQVIA’s monthly updates on the impact of COVID-19 and its implications for the healthcare ecosystem.

In the global effort to proactively fight COVID-19, the webinar series has been designed to:
•Provide some areas which pharma and biotech companies may wish to consider around the COVID-19 outbreak, in order to help guide our community through uncertain times
•Share key healthcare impact learnings from those countries that are ahead in the COVID-19 curve
•Look at how we can, together, best support patients, healthcare professionals, life sciences and governments to reduce the impact of the virus

This April webinar will take place on Thursday 23rd April from 12.30 to 13.30 (BST) / 07:30 to 08:30 (EST).

You can listen to our March webinar here: https://pharmaphorum.com/r-d/the-potential-impact-of-coronavirus-covid-19-for-global-pharma-and-biotech-continuity/

Focus

During the April instalment, our expert panel will discuss:
•Assessing the pharmaceutical market impact of COVID-19
•The UK clinical trials on COVID-19: navigating uncharted waters
•Genomics: research in the time of COVID-19
•Knowledge sharing: the COVID-19 experience from a US perspective
•Getting clinical research back up and running post-coronavirus
•Adjustments to new medicine launch planning

This pharmaphorum webinar will take place on 8th April and comes as the COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus vaccine.

Thrown into even sharper relief than usual are the needs faced by all vaccine trials to balance study speed, data accuracy and patient experience.

Additionally, given the fear of exposure and city mandates for individuals to stay at home, traditional patient recruitment challenges are exacerbated for a coronavirus trial. Placebo groups are unlikely to be used and the virus affects a very broad and non-discriminate patient population.

So, what is technology’s role in supporting the faster evaluation of vaccines? The right data capture technology can provide some important ways to first speed up vaccines research and then gain quicker regulatory submissions, compared with traditional paper records.

However, with patients’ expectations , it’s important to provide an experience of suitable quality to those who give up their time to take part in a study.

The pharmaphorum webinar Vaccines trials in the era of COVID-19 – balancing study speed, accuracy and patient experience is being held in association with ERT.

It is currently scheduled to take place on 8th April from 16:00 to 17:00 (BST) /11:00 to 12:00 (EST) and will look at how to balance trial speed, data accuracy and patient experience during the race for a coronavirus vaccine.

Focus
Our expert panel will discuss:
• Trial evolution so far and the impact of coronavirus
• Specific challenges for trial sponsors working on a coronavirus vaccine
• The impact of COVID-19 on patient attendance for studies
• Patient experience in vaccines clinical trials
• How to use virtual trial solutions, and when they’re not appropriate
• Efficient capture of patient data and RWE in rapid deployment trials

Overview
Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges.

Healthcare systems are being put under significant pressure, at a time when many are already over-stretched, medical congresses are being cancelled and bans on non-essential travel and enforced home working are emerging. Meanwhile, at local country level, Italy has gone into a country-wide lockdown and in China measures to prevent the virus’ spread have seen API manufacturing plants go offline.

This pharmaphorum webinar, held in association with IQVIA, will take place on Wednesday 18th March from 12:30-13:30 GMT with expert speakers outline potential scenarios, considerations and decisions that pharma and biotech would wish to plan for.

Focus
This COVID-19 continuity planning webinar will look at:
•COVID-19's potential impact on global pharmaceutical market dynamics
•Ways to support supply chain management
•Maintaining open lines of communication with healthcare professionals
•The application of artificial intelligence to potentially predict COVID-19 spread and patient infection
•Learning from China

Overview
In today’s digital world it is increasingly hard for pharmaceutical companies to successfully differentiate new brands based on their target product profile alone.

Instead, the key factor now is often the quality of customer engagement, which more and more healthcare professionals (HCPs) appear to value.

It’s enabled by a multichannel marketing (MCM) approach, but traditional MCM strategies require a much higher level of content than pharma is used to producing and approving – the answer to this is a modular approach.

Such modular content allows pharma to meet HCPs’ information demands by leveraging content assets across multiple channels and in many different combinations, at the same time providing superior targeting and tracking.

This pharmaphorum webinar, held in association with Anthill, will take place on Tuesday 17 March from 13:00 to 14:00 (GMT)/14:00 to 15:00 (CET) and will look at how the use of modular content in pharma can ease some digital worries.

Focus
Our expert panel will discuss:

•The most common challenges in the digital content creation process
•Aligning content creation tactics with the multichannel marketing strategy
•How to activate your existing content to maximise existing resource for the greatest HCP reach
•Making the customer experience a key differentiator

Our Panel
•Morten Kruse Sørensen, Global Director Multichannel Excellence and Operations, Novo Nordisk
•Florent Edouard, SVP, Global Head of Commercial Excellence, Grünenthal Group
•Huw Jenkins, Director, DAM Strategy, Veeva
•Kasper Jerlang, Head of Global Digital Marketing and Engagement, LEO Pharma
•Tor Kristensen, CTO, Anthill Agency
•Dominic Tyer, Creative and Editorial Director, pharmaphorum [moderator]

Chronic diseases are the leading cause of death and disability worldwide and have a staggering impact on patients’ lives and the provision of healthcare around the world.

Tackling conditions such as diabetes, heart disease and stroke is of vital importance if patient outcomes are to be improved and healthcare costs lowered.

To achieve this, and in doing so address clinical inertia, a combination of innovative communication strategies and behavioural science can provoke small changes that produce a meaningful difference in health outcomes.

This pharmaphorum webinar, in association with Complete HealthVizion, will look at how to help chronic disease patients to live well for longer, by providing a clear understanding of healthcare professionals’ and patients’ behaviours and communication needs.

Focus

The webinar will take place on Thursday 6th February from 14:00-15:00 GMT/09:00-10:00 EST, when a world-class faculty representing a wide-range of disciplines, including social science, multichannel and medical affairs strategy, will discuss how behavioural change approaches can be used to avoid major health problems and the increasing costs associated with declining health.

They will consider drivers of decision making in chronic disease management and look at why issues such as ‘behavioural complacency’ prevent progress and consider the lack of short-term benefits associated with many disease management approaches.

All too often there is little urgency to act in patients at risk from chronic disease, despite a growing burden that increases their suffering and the time they spend in clinical practices with HCPs.

This webinar will help change that, by looking at:

•How to assess readiness to change among patients and HCPs
•What strategic approaches work best in this setting
•How to target the most important HCPs and convince them of the need for change
•How to measure the effectiveness of behavioural change tactics

Overview

Patients are more informed than ever about their conditions and what is available for them to improve their quality of life.

The healthcare sector is increasingly focused on understanding patient needs and engaging them in the clinical development and medical information process. Therefore, it is paramount to create patient-focused educational content using a range of communication channels and digital tools.

However, do we take any time to think like a patient and, by doing so, understand their evolving needs and how this will affect the development of clinical trials and other healthcare educational initiatives?

This pharmaphorum webinar, held in association with Plenum and mdgroup, takes place on Wednesday 5th February from 14:00-15:00 GMT and will look at the impact of patient involvement, from clinical programme design through to launch and post-launch activities.

Focus

• What should patient-led communication look like and who will provide it?
• How to best meet patients’ needs during clinical trials
• Which meeting formats and other channels are most relevant to reach the broadest and most appropriate audiences?
• What role will each stakeholder play in the future?

Register to find out more and be part of this exciting debate.

Research from Ashfield Meetings & Events clearly demonstrates that face-to-face meetings and events form a major part of continuing medical education (CME). National and international congresses have been identified as the primary event to attend by HCPs.

But what makes congresses such a valuable education channel for time-restricted physicians? This pharmaphorum webinar, in association with Ashfield Meetings & Events, will dive into a unique study of HCP educational and behavioural preferences towards attendance at medical congresses.

Ashfield Meetings & Events’ The Science of Healthcare Congresses study, involved over 200 HCPs, drawn from a range of therapy areas, from both Europe and the US to ask what really matters to them and share some intriguing insights.

These encompassed how HCPs value this type of activity, how they apportion their time on-site and engage with the healthcare industry, and how they evaluate a congress once its doors have closed for another year.

Join our expert panel on Tuesday 3rd December to find out more on:

• Why physicians attend congresses
• How to ensure medical education provides value to attendees
• How pharma can enhance industry symposia

In addition, our panel will also share the results of an ongoing association and multi-pharmaceutical company research project, designed to standardise and benchmark the evaluation process of all congress medical education activities.

Pharmaceutical companies spend a huge amount of time and resources on creating valuable brand strategies, but when they come to life there’s often a disconnect.

Strategy and execution can easily drift apart when tactics come to life, making it harder for them to drive business and deliver on the long-term action plans to engage with healthcare professionals.

This is as true for eDetailing or closed-loop marketing initiatives as it is for multichannel marketing strategies that encompass the latest chatbot technology or innovative digital content platforms.

To remedy this, those working in pharma on multichannel marketing, brand planning and digital need to apply the human factor to their global brand strategies to achieve the kind of tactics that deliver on strategic goals.

Focus

Join Anthill on Thursday 28th November from 13:00 GMT / 14:00 CET for a live expert panel discussion on multichannel marketing, brand planning and how to apply global brand strategies in pharma to every customer interaction for greater HCP reach and return-on-investment.

In addition to looking at brand planning across pharma, common frustrations for the industry and whether or not brand planning is set up to deliver good multichannel marketing, the webinar will also cover:

• The most common challenges in the brand planning process
• How to build executional and strategic understanding across an entire brand plan
• How to activate your existing channels and create the best channel mix for customers
• How insight-based multichannel marketing can drive strategy and build new insights for the future

The pharmaceutical industry has been making great progress in its digital transformation, but boundaries are there to be pushed if companies want to continue to innovate their marketing practices and processes.

Overview
Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies).

Payers are in a difficult spot regarding the cost and management of these regimens. Traditional utilization management tools are still difficult to apply in oncology, given no payer wants to be on the front page of a major newspaper for denying treatment. Pathways have not held up to their promise for containing cost.

Personalized medicine approaches such as biomarkers serve an important role in targeting therapy to the most appropriate patients, thereby reigning in cost. However, there are limitations in the breadth and utility of these tools. For example, PD-1/PDL-1 drugs have shown conflicting outcomes associated with receptor expression – and these drugs are the backbone for many combo regimen programs in clinical development.

Environment/perception shifts, new approaches to management, indication-based pricing or other novel pricing approaches, and innovative payment models may hold promise for controlling cost in this new era of combination therapy.

Focus
Join ZS Associates for a live expert payer panel discussion on the challenges and potential solutions for managing the cost of combo oncology regimens. Topics will include:

•Perspectives on oncology drug management and combination regimen pricing today
•Potential payer-driven and pharma-driven solutions to price and cost management for oncology combo regimens
•What oncology manufacturers should consider in engaging payers in the future

The live payer webinar, co-moderated by Nicolle Hamilton, ZS Associates and Dominic Tyer, pharmaphorum, will take place on Wednesday, October 30 2019 from 14:00-15:15 GMT/10:00-11:15 ET.

Overview

The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care to specialty launch, but its future will be transformed even more radically.

The advent of highly novel cell and gene therapies as well as prescription digital therapeutics is providing a serious set of forces for change in the market.

Another comes from the challenges developed markets face, which renews the urgency for pharma companies to spread their launch successes beyond traditionally core markets.

The pressures exerted by these forces require companies’ efforts in launch excellence to be able to ‘square the circle’ of better launch returns even as the launch environment becomes ever-more complex.

To make sense of this landscape, this pharmaphorum webinar – in association with IQVIA – will look at the past, present and future of pharmaceutical launches. The event takes place on Wednesday 11th September from 11:00-12:00 BST.

Focus
•Traditional launch approaches: In the past, launch was defined as being the first two years of a product’s existence on the market. This is still a crucial time for any product’s launch, however, in an increasingly multi-indicational world, for many products, launch is no longer a one-off event.

•Current best practice in launch: Which launches have been the most commercially successful in recent years? By using IQVIA data the webinar will provide a unique view of the way in which commercial success has changed and look at what has driven the high-fliers.

•Future of launch excellence. The nature of innovation is changing very rapidly, and with it, both what is defined as launch, and the key capabilities and resources required for excellent launches. IQVIA experts will outline how to prepare for the future of launch excellence.

Overview

With pricing of drugs at the centre of political and social debate, the market access and pricing environment in Europe has become increasingly challenging over the years. Innovative contracting has since become a common route to overcome these challenges and ensure timely access for patients.


Focus

Join us on Monday 2nd September from 15:00-16:00 BST as we discuss the future of innovative contracting with our panel of European payers. Key topics to be covered include:

To what extent and how contracting helps improve patient access?
What prior successes and failures can teach us about designing contracts that deliver true value to the health systems?
Can we avoid contracting and what would be the alternative?

In the past decade, we have moved from simple discounting and traditional volume-based agreements to more complex value-based models involving measurement of health outcomes, risk-sharing and cost containment guarantees. The feasibility of these contracts tends to vary by EU market, dependent mainly on the available healthcare system infrastructure to collect and process data as well as other regulatory and philosophical differences.

Ultimately, the question remains as to whether these agreements are a move towards better healthcare provision and more connected healthcare infrastructures, or are they slowing down access and creating administrative burden due to their complexity?

Overview
Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST.

Customer journeys in pharma are changing, with important implications for the marketing supply chain. How can pharmaceutical marketers capitalise on this trend and free up budget to invest in additional marketing channels?

Focus
New developments in data and digital are changing traditional customer journeys and forcing pharmaceutical companies to evolve in order to keep up.

Companies like Apple and Amazon have elevated customer expectations for personalised content and interactions across multiple channels, in the process setting new standards for marketing. But, as they push the envelope, what are the implications for pharma’s work in customer engagement?

This pharmaphorum webinar, in association with Tag, will examine the challenges that pharma marketing faces to stay ahead of the evolving customer journey and offer expert insight from both the pharma and FMCG sectors on how to convert these challenges into opportunities .

The expert panel will consider exclusive research carried out by Tag and pharmaphorum across the US, Europe and Asia-Pacific among senior decision-makers in pharma and FMCG marketing.

The webinar, which takes place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST will also look at:
•How pharma currently allocates its marketing budgets
•Where marketers would like to have more money to invest
•How much time is spent directing creative ideation and managing marketing production

For more information, please visit:
https://pharmaphorum.com/digital/how-pharma-marketing-can-stay-ahead-of-the-evolving-customer-journey/